Ticker Details
Akebia Therapeutics, Inc. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.
IPO Date:	March 24, 2018
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$313.13M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.13 | 3.51%
Avg Daily Range (30 D):	$0.05 | 3.53%
Avg Daily Range (90 D):	$0.05 | 3.05%

Institutional Daily Volume
Avg Daily Volume:	2.82M
Avg Daily Volume (30 D):	3.12M
Avg Daily Volume (90 D):	3.53M

Trade Size
Avg Trade Size (Sh.):	317
Avg Trade Size (Sh.) (30 D):	333
Avg Trade Size (Sh.) (90 D):	341

Institutional Trades
Total Institutional Trades:	1,024
Avg Institutional Trade:	$1.63M
Avg Institutional Trade (30 D):	$.86M
Avg Institutional Trade (90 D):	$1.02M
Avg Institutional Trade Volume:	.47M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.55M
Avg Closing Trade (30 D):	$.63M
Avg Closing Trade (90 D):	$.99M
Avg Closing Volume:	470.13K

News

Feb 19, 2026 @ 1:00 PM Akebia Therapeutics to Report Fourth Quarter and F... Source: Na

Feb 4, 2026 @ 1:00 PM Akebia Therapeutics to Present at the Guggenheim E... Source: Not Specified

Dec 1, 2025 @ 2:43 PM Why Is Small-Cap Q32 Bio Stock Soaring On Monday? Source: Vandana Singh

Nov 6, 2025 @ 11:30 PM Vafseo® (vadadustat) Dialysis Dependent Patient... Source: Akebia Therapeutics

Jul 8, 2025 @ 12:00 PM Akebia Therapeutics to Present at the H.C. Wainwri... Source: Mercedes Carrasco

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.08	$	$
Diluted EPS	$-.08	$	$
Revenue	$225.07M	$58.77M	$62.47M
Gross Profit	$177.78M	$49.38M	$52.55M
Net Income / Loss	$-15.91M	$.54M	$.25M
Operating Income / Loss	$17.75M	$4.45M	$14.09M
Cost of Revenue	$47.29M	$9.38M	$9.92M
Net Cash Flow	$132.45M	$29.14M	$23.94M
PE Ratio